{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:27:27Z","timestamp":1741926447147,"version":"3.38.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.annder.2024.103323","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T15:40:58Z","timestamp":1730475658000},"page":"103323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Azacitidine-related pyoderma gangrenosum"],"prefix":"10.1016","volume":"152","author":[{"given":"S.","family":"Maral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Uzunabdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Zilan Yamis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kuzucular","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Surul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gokmen Sevindik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103323_b0005","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","article-title":"Pyoderma gangrenosum in hematologic malignancies: A systematic review","volume":"82","author":"Montagnon","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103323_b0010","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.jid.2019.12.040","article-title":"Next-generation sequencing in myeloid neoplasm associated sweet\u2019s syndrome demonstrates clonal relation between malignant cells and skin-infiltrating neutrophils","volume":"140","author":"Passet","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103323_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715053","article-title":"Myeloid clonal infiltrate identified with next-generation sequencing in skin lesions associated with myelodysplastic syndromes and chronic myelomonocytic leukemia: A case series","volume":"12","author":"Martin de Fr\u00e9mont","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.annder.2024.103323_b0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: A Delphi consensus of international experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103323_b0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","article-title":"Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine","volume":"85","author":"Santini","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.annder.2024.103323_b0030","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1111\/bjd.15773","article-title":"Image Gallery: Pyoderma gangrenosum in a patient with myelodysplastic syndrome treated with azacitidine","volume":"177","author":"Pardo Pastor","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103323_b0035","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3747\/co.25.3779","article-title":"Azacitidine-induced pyoderma gangrenosum at injection sites in a patient with myelodysplastic syndrome","volume":"25","author":"Roy","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.annder.2024.103323_b0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.13341","article-title":"Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome","volume":"169","author":"Tseng","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annder.2024.103323_b0045","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103323_b0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00128071-200203030-00002","article-title":"Clinical management of pyoderma gangrenosum","volume":"3","author":"Wollina","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2024.103323_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:30:09Z","timestamp":1741901409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0151963824000796"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103323","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azacitidine-related pyoderma gangrenosum","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103323"}}